Tenofovir may reduce risk of liver cancer in patients with HBV infection
the ONA take:
A new study published online ahead of print in the journal Cancer has shown that long-term therapy with tenofovir disoproxil fumarate (TDF) was associated with a decreased incidence of hepatocellular carcinoma among patients with chronic hepatitis B virus (HBV) infection without cirrhosis.
According to the American Cancer Society, there will be nearly 36,000 new cases of liver cancer diagnosed in the 2015 and about 24,550 people will die from the disease.
For the study, researchers analyzed data from the pivotal TDF registration studies that followed patients for 384 weeks. Of the 634 patients included for analysis, 152 had cirrhosis and 482 did not. During the study period, 14 patients developed hepatocellular carcinoma.
Results showed that the incidence of hepatocellular carcinoma was significantly lower than predicted among patients without cirrhosis.
TDF is an oral antiviral medication used to treat HIV infection in combination with other drugs and chronic HBV infection.
Long-term therapy with tenofovir was associated with a decreased incidence of HCC among patients with chronic HBV infection without cirrhosis.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- High U.S. Economic Burden for Vaccine-Preventable Diseases
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|